Clinical safety of tocilizumab in rheumatoid arthritis

A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab

(2014) Fumiaki Sugiura et al.   Modern Rheumatology

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

(2010) Gert J.D. Bergman et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

(2009) D E Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis?

(2009) Bruce H. Littman   ARTHRITIS AND RHEUMATISM

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis

(2009) R. M. Fleischmann   ARTHRITIS AND RHEUMATISM

Tocilizumab

(2009) Vicki Oldfield et al.   DRUGS

The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials

(2009) Mao Mao An et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’?

(2009) Robert J Moots et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Leukoencephalopathy with Cognitive Impairment following Tocilizumab for the Treatment of Rheumatoid Arthritis (RA)

(2009) Katsuya Kobayashi et al.   INTERNAL MEDICINE

Blockade of Interleukin 6 Signaling Induces Marked Neutropenia in Patients with Rheumatoid Arthritis

(2009) I. NAKAMURA et al.   JOURNAL OF RHEUMATOLOGY

Drug eruption induced by IL-6 receptor inhibitor tocilizumab

(2009) R Yoshiki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Rheumatoid arthritis

(2009) Lars Klareskog et al.   LANCET

Treatment of rheumatoid arthritis: state of the art 2009

(2009) Ronald F. van Vollenhoven   Nature Reviews Rheumatology

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Randomized Controlled Trials and Assessment of Drug Safety

(2008) David W J Clark et al.   DRUG SAFETY

Benefits and Risks of Drug Treatments

(2008) Jan P. Vandenbroucke et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Lipid Profiles in Patients with Rheumatoid Arthritis: Mechanisms and the Impact of Treatment

(2008) George Steiner et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM